uu.seUppsala universitets publikasjoner
Endre søk
Link to record
Permanent link

Direct link
BETA
Bergqvist, Michael
Publikasjoner (10 av 54) Visa alla publikasjoner
Willen, L., Berglund, A., Bergström, S., Bergqvist, M., Ojdahl-Boden, A., Wagenius, G. & Lambe, M. (2019). Educational level and management and outcomes in non-small cell lung cancer. A nationwide population-based study. Lung Cancer, 131, 40-46
Åpne denne publikasjonen i ny fane eller vindu >>Educational level and management and outcomes in non-small cell lung cancer. A nationwide population-based study
Vise andre…
2019 (engelsk)Inngår i: Lung Cancer, ISSN 0169-5002, E-ISSN 1872-8332, Vol. 131, s. 40-46Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Objectives: We examined associations between educational level and clinical presentation, patterns of management and mortality in patients with non-small cell lung cancer (NSCLC) in Sweden, a country with a National Health Care System. Materials and Methods: We identified 39,671 patients with a NSCLC diagnosis 2002-2016 in Lung Cancer Data Base Sweden (LCBaSe), a population-based research database. In analyses adjusted for comorbidity and other prognostic factors, odds Ratios (OR) and hazard Ratios (HR) were estimated to examine associations between patients' educational level and aspects of management and mortality. Results: Stage at diagnosis and waiting times did not differ between educational groups. In multivariable analysis, the likelihood to undergo PET/CT and assessment in a multidisciplinary team setting were higher in patients with high compared to low education (aOR 1.14; CI 1.05-1.23 and aOR 1.22; CI 1.14-1.32, respectively). In patients with early stage IA-IIB disease, the likelihood to undergo stereotactic radiotherapy was elevated in patients with high education (aOR 1.40; CI 1.03-1.91). Both all-cause (aHR 0.86; CI 0.77-0.92) and cause specific mortality (aHR 0.83; CI 0.74-0.92) was lower in patients with high compared to low education in early stage disease (IA-IIB). In higher stage NSCLC no differences were observed. Patterns were similar in separate assessments stratified by sex and histopathology. Conclusions: While stage at diagnosis and waiting times did not differ between educational groups, we found socioeconomic differences in diagnostic intensity, multidisciplinary team assessment, stereotactic radiotherapy and mortality in patients with NSCLC. These findings may in part reflect social gradients in implementation and use of novel diagnostic and treatment modalities. Our findings underscore the need for improved adherence to national guidelines.

sted, utgiver, år, opplag, sider
ELSEVIER IRELAND LTD, 2019
Emneord
Lung cancer, Non-small cell lung cancer, Socioeconomic status, Educational status, Population-based, Sweden
HSV kategori
Identifikatorer
urn:nbn:se:uu:diva-387553 (URN)10.1016/j.lungcan.2019.03.004 (DOI)000468721500006 ()31027696 (PubMedID)
Forskningsfinansiär
Swedish Cancer Society, 15-0804 18-0689
Tilgjengelig fra: 2019-06-25 Laget: 2019-06-25 Sist oppdatert: 2019-06-25bibliografisk kontrollert
Nilsson, J., Jaras, J., Henriksson, R., Holgersson, G., Bergström, S., Estenberg, J., . . . Bergqvist, M. (2019). No Evidence for Increased Brain Tumour Incidence in the Swedish National Cancer Register Between Years 1980-2012. Anticancer Research, 39(2), 791-796
Åpne denne publikasjonen i ny fane eller vindu >>No Evidence for Increased Brain Tumour Incidence in the Swedish National Cancer Register Between Years 1980-2012
Vise andre…
2019 (engelsk)Inngår i: Anticancer Research, ISSN 0250-7005, E-ISSN 1791-7530, Vol. 39, nr 2, s. 791-796Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Background/Aim: The main objective of this study was to evaluate if there was an increased incidence of brain tumours between years 1980-2012, a time period when mobile phone usage has increased substantially.

Materials and Methods: From the Swedish Cancer Registry, cases of meningiomas, low-grade gliomas (LGG) and high-grade gliomas (HGG) were identified in patients between 1980-2012. Direct age-standardised incidence rates were used to calculate incidence trends over time.

Results: A total of 13,441 cases of meningiomas, 12,259 cases of high-grade gliomas and 4,555 cases of LGG were reported to the register during the study period. The results suggest that there may be a negative development in the trend for LGG of -0,016 cases per 100,000 and year, corresponding to a mean reduction of approximately 1% per year.

Conclusion: The present study was not able to demonstrate an increased incidence of glioma during the past 30 years in Sweden.

sted, utgiver, år, opplag, sider
INT INST ANTICANCER RESEARCH, 2019
Emneord
Survival, brain tumours, incidence
HSV kategori
Identifikatorer
urn:nbn:se:uu:diva-377675 (URN)10.21873/anticanres.13176 (DOI)000457451200033 ()30711958 (PubMedID)
Forskningsfinansiär
Swedish Radiation Safety Authority
Tilgjengelig fra: 2019-02-25 Laget: 2019-02-25 Sist oppdatert: 2019-02-25bibliografisk kontrollert
Lugano, R., Vemuri, K., Yu, D., Bergqvist, M., Smits, A., Essand, M., . . . Dimberg, A. (2018). CD93 promotes β1 integrin activation and fibronectin fibrillogenesis during tumor angiogenesis.. Journal of Clinical Investigation, 128(8), 3280-3297
Åpne denne publikasjonen i ny fane eller vindu >>CD93 promotes β1 integrin activation and fibronectin fibrillogenesis during tumor angiogenesis.
Vise andre…
2018 (engelsk)Inngår i: Journal of Clinical Investigation, ISSN 0021-9738, E-ISSN 1558-8238, Vol. 128, nr 8, s. 3280-3297Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Tumor angiogenesis occurs through regulation of genes that orchestrate endothelial sprouting and vessel maturation, including deposition of a vessel-associated extracellular matrix. CD93 is a transmembrane receptor that is up-regulated in tumor vessels in many cancers, including high-grade glioma. Here, we demonstrate that CD93 regulates integrin-β1-signaling and organization of fibronectin fibrillogenesis during tumor vascularization. In endothelial cells and mouse retina, CD93 was found to be expressed in endothelial filopodia and to promote filopodia formation. The CD93 localization to endothelial filopodia was stabilized by interaction with multimerin-2 (MMRN2), which inhibited its proteolytical cleavage. The CD93-MMRN2 complex was required for activation of integrin-β1, phosphorylation of focal adhesion kinase (FAK) and fibronectin fibrillogenesis in endothelial cells. Consequently, tumor vessels in gliomas implanted orthotopically in CD93-deficient mice showed diminished activation of integrin-β1 and lacked organization of fibronectin into fibrillar structures. These findings demonstrate a key role of CD93 in vascular maturation and organization of the extracellular matrix in tumors, identifying it as a potential target for therapy.

Emneord
Brain cancer, Fibronectin, Oncology, Vascular Biology, endothelial cells
HSV kategori
Identifikatorer
urn:nbn:se:uu:diva-350902 (URN)10.1172/JCI97459 (DOI)000440461500015 ()29763414 (PubMedID)
Forskningsfinansiär
Swedish Cancer Society, CAN 2014/832Swedish Cancer Society, CAN 2017/502Swedish Cancer Society, CAN 2015/1216Swedish Childhood Cancer Foundation, PR2015-0133Swedish Childhood Cancer Foundation, NCP2015-0075Swedish Research Council, 2016-02495
Tilgjengelig fra: 2018-05-17 Laget: 2018-05-17 Sist oppdatert: 2018-11-08bibliografisk kontrollert
Zhang, L., He, L., Lugano, R., Roodakker, K. R., Bergqvist, M., Smits, A. & Dimberg, A. (2018). IDH mutation status is associated with distinct vascular gene expression signatures in lower-grade gliomas. Neuro-Oncology, 20(11), 1505-1516
Åpne denne publikasjonen i ny fane eller vindu >>IDH mutation status is associated with distinct vascular gene expression signatures in lower-grade gliomas
Vise andre…
2018 (engelsk)Inngår i: Neuro-Oncology, ISSN 1522-8517, E-ISSN 1523-5866, Vol. 20, nr 11, s. 1505-1516Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Background: Vascular gene expression patterns in lower-grade gliomas (LGGs; diffuse World Health Organization [WHO] grades II–III gliomas) have not been thoroughly investigated. The aim of this study was to molecularly characterize LGG vessels and determine if tumor isocitrate dehydrogenase (IDH) mutation status affects vascular phenotype.

Methods: Gene expression was analyzed using an in-house dataset derived from microdissected vessels and total tumor samples from human glioma in combination with expression data from 289 LGG samples available in the database of The Cancer Genome Atlas. Vascular protein expression was examined by immunohistochemistry in human brain tumor tissue microarrays (TMAs) representing WHO grades II–IV gliomas and nonmalignant brain samples. Regulation of gene expression was examined in primary endothelial cells in vitro.

Results: Gene expression analysis of WHO grade II glioma indicated an intermediate stage of vascular abnormality, less severe than that of glioblastoma vessels but distinct from normal vessels. Enhanced expression of laminin subunit alpha 4 (LAMA4) and angiopoietin 2 (ANGPT2) in WHO grade II glioma was confirmed by staining of human TMAs. IDH wild-type LGGs displayed a specific angiogenic gene expression signature, including upregulation of ANGPT2 and serpin family H (SERPINH1), connected to enhanced endothelial cell migration and matrix remodeling. Transcription factor analysis indicated increased transforming growth factor beta (TGFβ) and hypoxia signaling in IDH wild-type LGGs. A subset of genes specifically induced in IDH wild-type LGG vessels was upregulated by stimulation of endothelial cells with TGFβ2, vascular endothelial growth factor, or cobalt chloride in vitro.

Conclusion: IDH wild-type LGG vessels are molecularly distinct from the vasculature of IDH-mutated LGGs. TGFβ and hypoxia-related signaling pathways may be potential targets for anti-angiogenic therapy of IDH wild-type LGG.

Emneord
angiogenesis, ANGPT2, glioma, IDH, tumor vessel
HSV kategori
Identifikatorer
urn:nbn:se:uu:diva-352016 (URN)10.1093/neuonc/noy088 (DOI)000448665500010 ()29846705 (PubMedID)
Forskningsfinansiär
Swedish Cancer Society, CAN 2015/1216; CAN 2014/832; CAN 2017/502Swedish Childhood Cancer Foundation, PR2015-0133; NCP2015-0075Swedish Research Council, 2016-02495
Tilgjengelig fra: 2018-05-31 Laget: 2018-05-31 Sist oppdatert: 2019-01-08bibliografisk kontrollert
Nilsson, J., Holgersson, G., Jaras, J., Bergström, S. & Bergqvist, M. (2018). The role of income in brain tumor patients: a descriptive register-based study. Medical Oncology, 35(4), Article ID 52.
Åpne denne publikasjonen i ny fane eller vindu >>The role of income in brain tumor patients: a descriptive register-based study
Vise andre…
2018 (engelsk)Inngår i: Medical Oncology, ISSN 1357-0560, E-ISSN 1559-131X, Vol. 35, nr 4, artikkel-id 52Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Socioeconomic status (SES) and its association with cancer in general have been thoroughly studied in the last decades. Several studies have shown associations between SES and many types of cancer such as lung cancer, breast cancer, and prostate cancer. For gliomas, no clear occupational or exposure risk factors have been identified, although some possible risk factors such as use of cellular telephone are still controversial. The aim in the present study is to analyze whether there is an association between SES and development of brain cancer. Data from 1999 through 2013 were collected from the Swedish Cancer Registry and from the National Statistics of Sweden. Age-standardized incidence rates for people with different income were calculated using linear regression model. A total of 11,892 patients were included, of which 5675 were meningiomas, 1216 low-grade gliomas, and 5001 high-grade gliomas. No clear trend between increasing incidence rates and higher income was seen in neither of the investigated brain tumor histologies. In conclusion, the results should be interpreted with caution, but there does not seem to be a correlation in this material between increased income and development of brain cancer.

sted, utgiver, år, opplag, sider
Springer, 2018
Emneord
Brain cancer, Incidence trend, Income, Cancer Register, Socioeconomic status
HSV kategori
Identifikatorer
urn:nbn:se:uu:diva-351691 (URN)10.1007/s12032-018-1108-5 (DOI)000428784500009 ()29532282 (PubMedID)
Tilgjengelig fra: 2018-06-04 Laget: 2018-06-04 Sist oppdatert: 2018-06-04bibliografisk kontrollert
Byström, S., Fredolini, C., Edqvist, P.-H. D., Nyaiesh, E.-N., Drobin, K., Uhlen, M., . . . Schwenk, J. M. (2017). Affinity Proteomics Exploration of Melanoma Identifies Proteins in Serum with Associations to T-Stage and Recurrence. Translational Oncology, 10(3), 385-395
Åpne denne publikasjonen i ny fane eller vindu >>Affinity Proteomics Exploration of Melanoma Identifies Proteins in Serum with Associations to T-Stage and Recurrence
Vise andre…
2017 (engelsk)Inngår i: Translational Oncology, ISSN 1944-7124, E-ISSN 1936-5233, Vol. 10, nr 3, s. 385-395Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

BACKGROUND: Blood-based proteomic profiling may aid and expand our understanding of diseases and their different phenotypes. The aim of the presented study was to profile serum samples from patients with malignant melanoma using affinity proteomic assays to describe proteins in the blood stream that are associated to stage or recurrence of melanoma. MATERIAL AND METHODS: Multiplexed protein analysis was conducted using antibody suspension bead arrays. A total of 232 antibodies against 132 proteins were selected from (i) a screening with 4595 antibodies and 32 serum samples from melanoma patients and controls, (ii) antibodies used for immunohistochemistry, (iii) protein targets previously related with melanoma. The analysis was performed with 149 serum samples from patients with malignant melanoma. Antibody selectivity was then assessed by Western blot, immunocapture mass spectrometry, and epitope mapping. Lastly, indicative antibodies were applied for IHC analysis of melanoma tissues. RESULTS: Serum levels of regucalcin (RGN) and syntaxin 7 (STX7) were found to be lower in patients with both recurring tumors and a high Breslow's thickness (T-stage 3/4) compared to low thickness (T-stage 1/2) without disease recurrence. Serum levels of methylenetetrahydrofolate dehydrogenase 1-like (MTHFD1L) were instead elevated in sera of T3/4 patients with recurrence. The analysis of tissue sections with S100A6 and MTHFD1L showed positive staining in a majority of patients with melanoma, and S100A6 was significantly associated to T-stage. CONCLUSIONS: Our findings provide a starting point to further study RGN, STX7, MTHFD1L and S100A6 in serum to elucidate their involvement in melanoma progression and to assess a possible contribution to support clinical indications.

HSV kategori
Identifikatorer
urn:nbn:se:uu:diva-333614 (URN)10.1016/j.tranon.2017.03.002 (DOI)000407707600012 ()28433799 (PubMedID)
Forskningsfinansiär
Knut and Alice Wallenberg FoundationScience for Life Laboratory - a national resource center for high-throughput molecular bioscience
Tilgjengelig fra: 2017-11-16 Laget: 2017-11-16 Sist oppdatert: 2017-11-16bibliografisk kontrollert
Nilsson, J., Blomberg, C., Holgersson, G., Carlsson, T., Bergqvist, M. & Bergström, S. (2017). End-of-life care: Where do cancer patients want to die? A systematic review. Asian Perspectives, 13(6), 356-364
Åpne denne publikasjonen i ny fane eller vindu >>End-of-life care: Where do cancer patients want to die? A systematic review
Vise andre…
2017 (engelsk)Inngår i: Asian Perspectives, ISSN 0066-8435, E-ISSN 1535-8283, ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, ISSN 1743-7555, Vol. 13, nr 6, s. 356-364Artikkel, forskningsoversikt (Fagfellevurdert) Published
Abstract [en]

The importance to die at preferred death place is substantial among terminally ill cancer patients. Previously, several studies have investigated this issue, but no systematic review has been made for many years. This systematic review was made in order to investigate preferred death place among cancer patients. A systematic search was made in PubMed library and a total of 399 articles were found, of which 23 were eligible and included in the review. Preference of home death averaged by 59.9% (39.7–100%) across all studies. Information about actual death place was only reported in 12 studies with an average of 40.4% (14–65.2%); thus, the incongruence between preferred and actual death place seems to be substantial. This highlights the importance of health care providers to discuss the issue with the patients and their families. However, study designs must improve and publications of socioeconomic data should be unified to ease interpretation in future studies.

Emneord
palliative end-of-life care, preferred death place
HSV kategori
Identifikatorer
urn:nbn:se:uu:diva-356246 (URN)10.1111/ajco.12678 (DOI)000427541000004 ()28294576 (PubMedID)
Tilgjengelig fra: 2018-07-27 Laget: 2018-07-27 Sist oppdatert: 2018-07-27bibliografisk kontrollert
Nilsson, J., Holgersson, G., Carlsson, T., Henriksson, R., Bergström, S. & Bergqvist, M. (2017). Incidence trends in high-grade primary brain tumors in males and females. Oncology Letters, 13(4), 2831-2837
Åpne denne publikasjonen i ny fane eller vindu >>Incidence trends in high-grade primary brain tumors in males and females
Vise andre…
2017 (engelsk)Inngår i: Oncology Letters, ISSN 1792-1074, E-ISSN 1792-1082, Vol. 13, nr 4, s. 2831-2837Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

The focus of the present review is to investigate whether there is a variation in the incidence rates between male and female patients with high-grade primary brain tumors and if there are altered incidence rates associated with the time at which they were diagnosed. Previous studies identified in internationally peer-reviewed journals were identified using a systematic search of the PubMed database. Due to the difficulties in data interpretation, studies that exclusively included patient data classified prior to the 2nd edition of the World Health Organization histological classification system of brain tumors were excluded. The overall incidence rates and incidence trends of male and female patients were analyzed separately. The mean age-adjusted overall incidence rate in the male population was 1.27 per 100,000 compared with 0.89 per 100,000 in the female population. The variance between the two genders differed and a Wilcoxon rank-sum test indicated that there was no significant difference in the incidence rate of high-grade primary brain tumors between males and females (P=0.3658). Furthermore, there was no significant difference in incidence rate trend between 1996-2004 and 2005-2010 for male or female populations (P=0.101 and P=0.472, respectively). The results from the present systematic review did not demonstrate a significant difference in incidence rate between the two genders. Therefore, the results from the current study are considered to be preliminary and further studies are required to elucidate this issue.

Emneord
incidence trends, high-grade brain tumors, gender
HSV kategori
Identifikatorer
urn:nbn:se:uu:diva-321444 (URN)10.3892/ol.2017.5770 (DOI)000398514200119 ()
Tilgjengelig fra: 2017-05-05 Laget: 2017-05-05 Sist oppdatert: 2017-05-05
Bergqvist, M., Holgersson, G., Bondarenko, I., Grechanaya, E., Maximovich, A., Andor, G., . . . Harmenberg, J. (2017). Phase II randomized study of the IGF-1R pathway modulator AXL1717 compared to docetaxel in patients with previously treated, locally advanced or metastatic non-small cell lung cancer. Acta Oncologica, 53(3), 441-447
Åpne denne publikasjonen i ny fane eller vindu >>Phase II randomized study of the IGF-1R pathway modulator AXL1717 compared to docetaxel in patients with previously treated, locally advanced or metastatic non-small cell lung cancer
Vise andre…
2017 (engelsk)Inngår i: Acta Oncologica, ISSN 0284-186X, E-ISSN 1651-226X, Vol. 53, nr 3, s. 441-447Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

BACKGROUND: The primary objective of this study was to compare the progression-free survival (PFS) at 12 weeks between patients treated with IGF-1R pathway modulator AXL1717 (AXL) and patients treated with docetaxel (DCT).

MATERIAL AND METHODS: The study was conducted at 19 study centers in five countries. A total of 99 patients with previously treated, locally advanced or metastatic non-small cell lung cancer (NSCLC) of the squamous cell carcinoma (SCC) or adenocarcinoma (AC) subtypes in need of additional treatment were randomized and treated with either 300 or 400 mg of AXL as daily BID treatment (58 patients) or DCT given as 75 mg/m(2) in three-week cycles (41 patients) as monotherapy in a 3:2 ratio for each NSCLC subtype. Patients were treated in the primary study treatment period for a maximum of four treatment cycles.

RESULTS: The 12-week PFS rate, median PFS and overall survival (OS), as well Kaplan-Meier hazard ratio for PFS and OS, did not show any statistically significant differences between the treatment groups. For the primary endpoint, the AXL group had a lower percentage of patients (25.9%) who were progression-free at Week 12 as compared to the DCT group (39.0%), although the difference was not statistically significant. The most notable difference in the incidence of treatment emergent adverse effects (TEAEs) was the lower incidence of treatment-related grade 3/4 neutropenia in patients treated with AXL.

CONCLUSION: These results suggest neither of the treatments to be superior of the other when treating locally advanced or metastatic NSCLC. Considering the lower incidence of grade 3/4 neutropenia in the AXL group this treatment warrants further research.

HSV kategori
Identifikatorer
urn:nbn:se:uu:diva-312364 (URN)10.1080/0284186X.2016.1253866 (DOI)000396774900011 ()27882820 (PubMedID)
Tilgjengelig fra: 2017-01-09 Laget: 2017-01-09 Sist oppdatert: 2017-11-29bibliografisk kontrollert
Holgersson, G., Bergström, S., Hallqvist, A., Liv, P., Nilsson, J., Willen, L., . . . Bergqvist, M. (2017). The prognostic value of pre-treatment thrombocytosis in two cohorts of patients with non-small cell lung cancer treated with curatively intended chemoradiotherapy. Neoplasma (Bratislava), 64(6), 909-915
Åpne denne publikasjonen i ny fane eller vindu >>The prognostic value of pre-treatment thrombocytosis in two cohorts of patients with non-small cell lung cancer treated with curatively intended chemoradiotherapy
Vise andre…
2017 (engelsk)Inngår i: Neoplasma (Bratislava), ISSN 0028-2685, E-ISSN 1338-4317, Vol. 64, nr 6, s. 909-915Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Chemoradiotherapy is the standard of care for inoperable stage III non-small cell lung cancer (NSCLC). This treatment, however, offers only a small chance of cure and is associated with many side effects. Little research has been made concerning which patients benefit most/least from the treatment. The present study evaluates the prognostic value of anemia, leukocytosis and thrombocytosis at diagnosis in this treatment setting. In the present study, data were collected retrospectively for 222 patients from two different phase II studies conducted between 2002-2007 in Sweden with patients treated with chemoradiotherapy for stage IIIA-IIIB NSCLC. Clinical data and the serum values of hemoglobin (Hgb), White blood cells (WBC) and Platelets (Plt) at enrollment were collected for all patients and studied in relation to overall survival using Kaplan-Meier product-limit estimates and a multivariate Cox proportional hazards regression model.

The results showed that patients with thrombocytosis (Plt > 350 x 109/L) had a shorter median overall survival (14.5 months) than patients with normal Plt at baseline (23.7 months). Patients with leukocytosis (WBC > 9 x 109/L) had a shorter median survival (14.9 months) than patients with a normal WBC at baseline (22.5 months). However, in a multivariate model including all lab parameters and clinical factors, only thrombocytosis and performance status displayed a prognostic significance.

In Conclusion, thrombocytosis showed to be an independent prognostic marker associated with shorter overall survival in stage III NSCLC treated with curatively intended chemoradiotherapy. This knowledge can potentially be used together with established prognostic factors, such as performance status when choosing the optimal therapy for the individual patient in this clinical setting.

Emneord
NSCLC, anemia, leukocytosis, thrombocytosis, prognostic, survival
HSV kategori
Identifikatorer
urn:nbn:se:uu:diva-339512 (URN)10.4149/neo_2017_614 (DOI)000418756500013 ()28895417 (PubMedID)
Tilgjengelig fra: 2018-01-19 Laget: 2018-01-19 Sist oppdatert: 2018-01-19bibliografisk kontrollert
Organisasjoner